This document provides guidelines to Gilead’s grantees, those who have received funding through Gilead Sciences, Inc.’s (“Gilead”) Corporate Giving program, how to use the GILEAD Logo appropriately.
Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer & inflammation.
Gilead and Genesis Therapeutics Announce Strategic …
Sep 10, 2024 · Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and …
Gilead and Tubulis Enter Into Exclusive Option and License …
Dec 3, 2024 · The Tubulis name and logo are trademarks of Tubulis. For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information.
Gilead and LEO Pharma Enter Into Strategic Partnership to …
Jan 11, 2025 · Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. The LEO Pharma name and logo are trademarks of LEO Pharma. For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Gilead Prices 3.5 Billion of Senior Unsecured Notes
Nov 13, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering ...
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy ...
Dec 17, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy ® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has ...
Gilead Sciences, Inc. - Gilead Sciences Appoints Dietmar Berger, …
Dec 12, 2024 · Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on X/Twitter (@Gilead Sciences) and …
Gilead and Galapagos Announce New Commercialization and …
Dec 15, 2020 · -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU --